FindTrial
Sign In

F/TDF

DRUG4 trials

Sponsors

Gilead Sciences

Conditions

HIV-1/HBV Co-InfectionPre-Exposure Prophylaxis of HIV InfectionPre-Exposure Prophylaxis of HIV-1 Infection

Phase 3

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Active, not recruitingNCT02842086
Gilead SciencesPre-Exposure Prophylaxis of HIV-1 Infection
Start: 2016-09-02End: 2027-09-30Updated: 2025-11-13
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults
CompletedNCT03547908
Gilead SciencesHIV-1/HBV Co-Infection
Start: 2018-05-30End: 2024-03-07Updated: 2025-03-19
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
Active, not recruitingNCT04925752
Gilead SciencesPre-Exposure Prophylaxis of HIV Infection
Start: 2021-06-28End: 2028-08-31Updated: 2025-12-23
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
Active, not recruitingNCT04994509
Gilead SciencesPre-Exposure Prophylaxis of HIV Infection
Start: 2021-08-30End: 2028-01-01Updated: 2026-03-30

Related Papers

P-299. No Clinically Significant Drug-Drug Interactions Between Lenacapavir and Hormonal Contraceptives in PURPOSE 1
Open Forum Infectious Diseases2026-01-01
392. Favorable Adherence and Safety of Twice-Yearly Subcutaneous Lenacapavir for PrEP Among PURPOSE 2 Participants Who Used Substances
Open Forum Infectious Diseases2026-01-01
P-305. No Clinically Significant Drug–Drug Interactions with Co-administration of Feminizing or Masculinizing Hormone Therapy and Twice-yearly Lenacapavir PrEP in Gender-Diverse Persons
Open Forum Infectious Diseases2026-01-01
Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLIANCE Study.
2025-12-01
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial
2025-02-01
HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo
UNC Libraries2025-01-30
P-512. Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis (PrEP): A Real-World Study
Open Forum Infectious Diseases2025-01-29
Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy
UNC Libraries2024-12-04
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
New England Journal of Medicine2024-11-27159 citations
Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy
Journal of Antimicrobial Chemotherapy2024-11-185 citations
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
New England Journal of Medicine2024-07-24338 citations
HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial.
2024-07-143 citations
Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data
JAIDS Journal of Acquired Immune Deficiency Syndromes2024-04-253 citations
Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis: A Subgroup Analysis from the DISCOVER Trial.
2024-01-3111 citations
HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo
The Journal of Infectious Diseases2023-11-161 citations
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.
2023-07-2333 citations
2059. Estimated Background HIV Diagnosis Rates among People Who Could Benefit from Pre-Exposure Prophylaxis (PrEP) at the Metropolitan Statistical Area (MSA) level in the United States, 2012-2019
Open Forum Infectious Diseases2022-12-01
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
PLoS ONE2022-06-0339 citations
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
2021-07-0165 citations
Using the adherence‐efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background HIV incidence: a secondary analysis of a randomized, controlled trial
Journal of the International AIDS Society2021-05-0120 citations

2 more papers not shown